Infliximab (Remicade), which blocks tumor necrosis factor-α (TNF-α), is approved for maintaining clinical remission and mucosal healing in patients with moderately to severely active ulcerative colitis and who have had an inadequate response to conventional therapy. The approval is based primarily on a study that found patients on infliximab were twice as likely to be in remission at week 54, than those on placebo, according to Centocor (www.centocor.com